Leukemia Therapeutics Market Advancements to Watch Out For 2026
Leukemia also known
as blood cancer hinders ability of an individual to fight infection.
It is characterized by formation of tumors in blood-forming tissues
including bone marrow. Various type of leukemia include acute
lymphoblastic leukemia, acute myeloid leukemia, and chronic
lymphocytic leukemia. Fatigue, weight loss, frequent infections and
easy bleeding or bruising are some of the symptoms of this disease.
Treatment of early leukemia include monitoring and severe leukemia is
treated with chemotherapy, followed by radiation and stem-cell
transplant. According to Center for Disease Control and Prevention
(CDC), in the U.S. around 45,360 people were diagnosed with leukemia
in 2013, leading to 23,549 fatalities (13,625 men and 9,924 women).
The condition is more prevalent among men than women.
Download The PDF
Brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/528
Leukemia
Therapeutics Market
On the basis of
disease condition, the global leukemia therapeutics market is
segmented into:
-
Acute lymphocytic leukemia
-
Chronic lymphocytic leukemia
-
Acute myeloid leukemia
-
Chronic myeloid leukemia
On the basis of
treatment, the global leukemia therapeutics market is segmented into:
-
Immunotherapy
-
Targeted Therapy
-
Bone Marrow Transplant
-
Stem Cell Therapy
High
diagnosis rate in developed economies supporting the leukemia
therapeutics market growth in those regions
According to the
Centre for Disease Control (CDC), around 14.1 million people were
diagnosed with cancer in 2012, resulting in around 8.2 million
fatalities. Around 19.3 million new cases of cancer are projected to
be diagnosed by 2025. Leukemia cases are projected to be more in the
developed economies such as North America and Europe, owing to
genetic mutations caused by radiation exposure. There are about
54,270 new cases of leukemia in the U. S. annually. Leukemia makes up
about 3% of all new cancer cases. According to the World Cancer
Research Fund, one third of the cancer cases occur in economically
developed economies such as US and Europe, owing to lack of physical
activity, obesity, and/or poor nutrition. Furthermore, around 90% of
the leukemia occur in the middle age and develop with the aging.
Furthermore, in
emerging economies of Asia Pacific such as China and India, the
leukemia therapeutics market is expected to grow at significant rate
due high unmet medical needs. However, low diagnosis rate of leukemia
and lack of proper healthcare facilities in few Asian and African
countries is restraining growth of the leukemia therapeutics market
in these regions.
Key players
operating in the global leukemia therapeutics market include GSK,
Eisai C., Pfizer, Biogen, Celgene, Novartis AG, Genzyme Corporation,
Roche, and Bristol Myers Squibb Company (BMS). Major market players
are focused on new product launch, product pipeline, merger &
acquisitions, clinical trials and collaboration & agreements to
maintain leading position in market. For instance, Novartis recently
launched tyrosine kinase receptor FLT-3 for the treatment of
leukemia. Pfizer implemented product expansion strategy to capture
major market share, received Food and Drug Approval (FDA) for Bosulif
drug.
Click To Read
More Leukemia
Therapeutics Market
About
Us:
Coherent Market Insights is a prominent market research and
consulting firm offering action-ready syndicated research reports,
custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Comments
Post a Comment